Lundbeck
HLUN-B.COApprovedLundbeck is a specialized biopharmaceutical company dedicated entirely to brain diseases, distinguishing itself as one of the few companies worldwide with this exclusive focus. The company leverages over seven decades of neuroscience expertise to develop and commercialize therapies for psychiatric and neurological disorders, including depression, schizophrenia, Alzheimer's disease, and migraine. As a 'Focused Innovator,' Lundbeck is building on its legacy to serve neuro-rare communities through bold science and deep patient commitment. The company operates globally, with approximately 1,000+ colleagues in the U.S. alone, working to deliver innovative treatments and support patient communities.
HLUN-B.CO · Stock Price
Historical price data
AI Company Overview
Lundbeck is a specialized biopharmaceutical company dedicated entirely to brain diseases, distinguishing itself as one of the few companies worldwide with this exclusive focus. The company leverages over seven decades of neuroscience expertise to develop and commercialize therapies for psychiatric and neurological disorders, including depression, schizophrenia, Alzheimer's disease, and migraine. As a 'Focused Innovator,' Lundbeck is building on its legacy to serve neuro-rare communities through bold science and deep patient commitment. The company operates globally, with approximately 1,000+ colleagues in the U.S. alone, working to deliver innovative treatments and support patient communities.
Technology Platform
Deep, integrated neuroscience expertise focused on CNS drug discovery and development, translational research, and external innovation partnerships, built over 70+ years of specialization in brain diseases.
Pipeline Snapshot
358358 drugs in pipeline, 121 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Vortioxetine | Major Depressive Disorder | Approved | |
| Memantine (once daily) + Memantine (twice daily) | Alzheimer Dementia (AD) | Approved | |
| Eptinezumab | Migraine | Approved | |
| Memantine | Alzheimer's Disease | Approved | |
| 20 mL ropivacaine 5 mg/mL + 10 mL ropivacaine 10 mg/mL | Postoperative Pain | Approved |
FDA Approved Drugs
6Opportunities
Risk Factors
Competitive Landscape
Lundbeck faces competition from large pharma (e.g., AbbVie, Eli Lilly, Johnson & Johnson) and specialized biotechs in psychiatry, migraine (CGRP competitors like Amgen, Pfizer), and neurodegeneration. Its primary differentiation is its exclusive, decades-long focus on brain diseases, resulting in deep integrated neuroscience expertise and a patient-centric approach to development and commercialization.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile